MyMedR

Displaying all 5 publications

Abstract:

Sort:

Evaluation of semen collected by electroejaculation from captive lesser Malay chevrotain (Tragulus javanicus)

Haron AW, Ming Y, Zainuddin ZZ

J. Zoo Wildl. Med., 2000 Jun;31(2):164-7.
PMID: 10982126

Thirteen sexually mature captive male lesser Malay chevrotains (Tragulus javanicus) were each anesthetized twice with tiletamine-zolazepam for electroejaculation. Viable spermatozoa were collected from all animals. The semen was creamy, milky, pale yellowish, or watery. The mean values for ejaculate volume, sperm concentration, and percentages of sperm motility, normality and viability were 23.7 +/- 2.5 microl, 366.9 +/- 127.8 x 10(6) spermatozoa/ml, 40.0% +/- 3.1%, 71.4% +/- 1.6%, and 59.6% +/- 2.1%, respectively. Semen pH was 7-8. No adverse effects of electroejaculation were noted. These are the first reported values for semen of lesser Malay chevrotain. Electroejaculation should be usable for routine semen collection in this species.
Budget Impact of Emicizumab for Routine Prophylaxis of Bleeding Episodes in Patients With Hemophilia A With Inhibitors

Watanabe AH, Lee SWH, Chai-Adisaksopha C, Lim MY, Chaiyakunapruk N

Value Health Reg Issues, 2021 Nov 17;28:7-13.
PMID: 34800834 DOI: 10.1016/j.vhri.2021.07.003

OBJECTIVES: To examine the budget impact of emicizumab as prophylactic therapy in reducing the frequency of bleeding episodes in patients with hemophilia A with inhibitors in Malaysia.
METHODS: A budget impact model was built to assess the cost implication of introducing emicizumab for routine prophylaxis of bleeding episodes in people with hemophilia A with inhibitors. It was based on the public healthcare system in Malaysia over a 5-year duration. The primary analysis computed healthcare costs for emicizumab compared with no prophylactic regimen to calculate the budget needed to treat all patients with hemophilia A with inhibitors.
RESULTS: The introduction of emicizumab resulted in a total incremental budget of Malaysian Ringgit (RM) 20 356 897 ($4 917 125) during the first year. The total cost for the current situation (no prophylaxis) was RM13 425 941 ($3 242 981), whereas the total cost for the new situation (prophylaxis with emicizumab) was RM33 782 838 ($8 160 106). The 5-year cumulative incremental budget impact from 2021 to 2025 was RM97 205 459 ($23 479 579) with an uncertainty range from -RM4 869 886 (-$1 176 301) to RM138 035 597 ($33 341 932) and a total of 72 patients treated with emicizumab. In a sensitivity analysis, the use of emicizumab was cost saving if the annual bleeding rate was greater than 16 instead of 6 times per year.
CONCLUSION: The 5-year budget impact might be considered reasonable and possibly cost saving. The model and approach used in this study to obtain relevant parameters where scarce data exist may help other jurisdictions with future adaptation.
Male-specific RNA coliphages detected by plaque assay and RT-PCR in tropical river waters and animal fecal matter

Yee SY, Fong NY, Fong GT, Tak OJ, Hui GT, Su Ming Y

Int J Environ Health Res, 2006 Feb;16(1):59-68.
PMID: 16507481

Male-specific RNA coliphages (FRNA) have been recommended as indicators of fecal contamination and of the virological quality of water. In this study, 16 river water and 183 animal fecal samples were examined for the presence of FRNA coliphages by a plaque assay using Salmonella typhimurium WG49 and WG25 to differentiate between male-specific and somatic phages, a RNase spot test to differentiate between DNA and RNA phages and a reverse transcriptase-polymerase chain reaction (RT-PCR) for the specific identification of FRNA phages. The overall recovery rate for F-specific coliphages was 8.0%. (4.4% from animal fecal matter and 50% from river water samples). Plaque counts were generally low (< 6 x 10(2) pfu per g feces or ml water), with FRNA (6.5%) and Male-specific DNA coliphages (FDNA) (7.0%) phages occurring at almost equal frequencies. The RT-PCR was positive in all FRNA plaques and was able to identify FRNA phages in mixed populations of FRNA, FDNA and somatic phages.
Biosynthesis, Characterization and Biological Activities of Silver Nanoparticles from Pogostemon cablin Benth. Methanolic Leaf Extract

Qing S, Shoutian Q, Hongyan G, Ming Y, Swamy MK, Sinniah UR, et al.

J Nanosci Nanotechnol, 2019 07 01;19(7):4109-4115.
PMID: 30764978 DOI: 10.1166/jnn.2019.16282

This study reports the biosynthesis of silver nanoparticles (AgNPs) using methanolic leaf extract of Pogostemon cablin Benth. (Patchouli) as a reducing agent, and their potent biological (antibacterial, antioxidant and anticancer) activities. The P. cablin extract when exposed to silver nitrate reduced silver ions to form crystalline AgNPs within 1 h of incubation at room-temperature. UV-visible spectra showed a sharp surface plasmon resonance (SPR) at around 430 nm for the biosynthesized AgNPs and the XRD pattern indicated the crystalline planes of the face centered cubic silver. The FE-SEM analysis revealed the occurrence of predominant spherical shaped AgNPs with a huge disparity in their particle size distribution with an average size of 25 nm, while, the FTIR data confirmed the bio-reduction and capping of AgNPs by several phytocompounds present in the methanolic leaf extract. AgNPs effectively inhibited the growth of all the tested human pathogenic bacterial strains (Bacillus subtilis, Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli), while, the methanolic leaf extract failed to inhibit the growth of S. aureus and P. aeruginosa. AgNPs showed the highest free radical scavenging activity (79.0 ± 0.76%) compared to methanolic leaf extract (68.3 ± 0.68%) at 100 μg/ml. Further, the cytotoxicity study using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) confirmed that AgNPs successfully inhibited the human colon adenocarcinoma cell line (HT-29) in a dose dependent manner. At higher concentrations (500 μg/ml), only 4% of cells survived after 72 hrs of exposure with IC50 value of 120 μg/ml. Thus, these findings offer a new source of biomolecules with diverse biological activities.
Evaluation of an Initiation Regimen of Warfarin for International Normalized Ratio Target 2.0 to 3.0

Mohamed S, Mei Fong C, Jie Ming Y, Naila Kori A, Abdul Wahab S, Mohd Ali Z

J Pharm Technol, 2021 Dec;37(6):286-292.
PMID: 34790965 DOI: 10.1177/87551225211034175

Background: he number of patients on warfarin therapy is rising steadily. Although warfarin is beneficial, it carries a high risk of bleeding, especially if the international normalized ratio (INR) values exceed 3.0. Currently, no warfarin initiation regimens have been developed for the Asian population, especially for Malaysians. Objective: This article describes the efficacy and safety of a new initiation regimen for warfarin among warfarin-naive patients. Method: Data were retrospectively collected from the ambulatory and inpatient settings. Results: A total of 165 patients who each had a target INR of 2.0 to 3.0 were included in the study. The mean age was 57.2 years and 94 patients were male. A total of 108 patients used Regimen 1 (5 mg/5 mg/3mg) and the rest of the patients used Regimen 2 (5 mg/3 mg/3 mg). Most patients used warfarin either for atrial fibrillation (52.1%) or for venous thromboembolism (29.7%). Overall, 88 of the patients had INR values above 50% from the baseline on Day 4. Additionally, 13 patients had INR values of >3.2, which required withholding and lower dose of warfarin. The predicted weekly maintenance warfarin dose (23 ± 0.5 mg/week) was found to have correlated closely with the actual maintenance dose (22.8 ± 0.5 mg/week; r 2 = 0.75). Nearly two thirds (70.3%) of the patients achieved the target INR on Day 11. Conclusion: The warfarin initiation regimens in this study was simple, safe, and suitable to be used in both ambulatory and inpatient settings for managing warfarin therapy.